Session 1: What I always wanted to know from other specialists? (90 min)

1. Surgeon’s perspective (7 min)

Vincent Fang (Shanghai Chest Hospital, Shanghai, China)

2. Radiologist’s perspective (7 min)

Jeanne Ackman (Harvard Medical School, Massachusetts General Hosptial, Boston, MA, USA)

3. Pathologist’s perspective (7 min)

Anja Roden (Mayo Clinic, Rochester, USA)

4. Neurologist’s perspective (7 min)

Mohammad Ashraghi (Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford, UK)

5. Radiation oncologist’s perspective (7 min)

Charles Simone (Memorial Sloan Kettering Cancer Center and New York Proton Center, New York, USA)

6. Medical oncologist’s perspective (7 min)

Chul Kim (Georgetown University, Washington, DC, USA)

7. Case presentation – Consequences of the lack of communication (10 min)

Arya Amini (City of Hope National Medical Center, Los Angeles, CA, USA)

Q&A (30 min), moderators: Andreas Rimner (Memorial Sloan Kettering Cancer Center, New York, USA), Edith M. Marom (The Chaim Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel)

Session 2:  Lymph node involvement in thymic epithelial tumors (1 hr 15 min)

1. Imaging of mediastinal lymph nodes (CT, MRI, PET/CT) (10 min)

Chad Strange (University of Texas MD Anderson Cancer Center, Houston, TX, USA)

2. Nodal dissection in TETs – how much is enough? (10 min)

Wing Kea Hui (Antwerp University Hospital, Antwerp, Belgium)

3. pN factor in pathological report (10 min)

Malgorzata Szolkowska (Institute of Tuberculosis and Lung Diseases, Warsaw, Poland)

4. Radiation oncology treatment fields: nodal coverage and target volume delineation (10 min)

Florit Marcuse (Maastricht University Medical Center, Maastricht, The Netherlands)

5. Survival in relation to nodal involvement in TET (10 min)

Chuong Hoang (National Cancer Institute – NIH, Bethesda, USA)

Q&A (25 min), moderators: Paul Van Schil (Antwerp University Hospital, Antwerp, Belgium), Andrea Bezjak (Princess Margaret Cancer Centre, Toronto, Canada)

Session 3: Lung carcinomas vs. thymic carcinomas (90 min)

1. The role of minimally invasive surgery in lung carcinomas and in thymic carcinomas (15 min)

Joshua Sonett (Columbia University/New York-Presbyterian Hospital, New York, USA)

2. Biomarkers for targeted therapies in lung carcinomas and in thymic carcinomas – state-of-the-art and future perspectives (15 min)

Jan von der Thüsen (Erasmus MC, Rotterdam, The Netherlands)

3. Radiation therapy for lung carcinomas and for thymic carcinomas (15 min)

Conrad Falkson (Queen’s University and CCSEO @ KHSC, Kingston, Canada)

4. Molecular targeted therapies and immunotherapy in lung carcinomas and in thymic carcinomas (15 min)

Sukhmani Padda (Cedars-Sinai Medical Center, Los Angeles, USA)

Q&A (30 min), moderators: Nicolas Girard (Institut Curie, Paris, France)

Session 4: Complications and side effects of the treatment in TETs  (1 hr 10 min)

1. The most important complications of surgical treatment of TETs (10 min)

Dirk Van Raemdonck (University Hospitals Leuven, Leuven, Belgium)

2. Side effects of radiotherapy for TETs (10 min)

Annemarie Shepherd (Memorial Sloan Kettering Cancer Center, New York, NY, USA)

3. Cardiotoxicity and other longterm toxicities of chemotherapy for TETs (10 min)

Sebastian Szmit (Centre of Postgraduate Medical Education & Institute of Hematology and Transfusion Medicine, Warsaw, Poland)

4. Autoimmune side effects of immunotherapy for TETs (10 min)

Arun Rajan (National Cancer Institute, National Institutes of Health, Bethesda, USA)

Q&A (30 min), moderators: Stephanie Peeters (Maastro, Maastricht, The Netherlands), James Huang (Memorial Sloan Kettering Cancer Center, New York, NY, USA)

ORAL ABSTRACT SESSION (Recording available when you purchase access to the entire conference)

1. (AB 01) Surgical resection followed by entire hemithorax irradiation in patients with stage IVa thymoma: preliminary result of a prospective phase II study, Changlu Wang, Shanghai Chest Hospital, Shanghai, China
2. (AB 07) Effectiveness of chemotherapy as the first-line treatment for thymic tumors with pleural dissemination, Xuefei Zhang, Shanghai Chest Hospital, Shanghai, China
3. (AB 08) Expression of Trop2 in thymic epithelial tumors, Vincent Yeung, Rutgers Cancer Institute of New Jersey, University Hospital, Newark, NJ, USA
4. (AB 09) Activated pathways of thymic epithelial tumors: a RYTHMIC study, Benitez Jose Carlos, Cancer Medicine Department Gustave Roussy, Villejuif, France
5. (AB 13) Automated histologic subtyping of thymic epithelial tumors with deep learning, James M. Dolezal, University of Chicago Medicine, Chicago IL, USA
6. (AB 14) Treatment of thymic oligometastastic or oligoprogressive lesions with hypofractionated radiation therapy or stereotactic body radiation therapy, Christopher B. Jackson, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Moderators: Tibor Krajc (Klinik Floridsdorf, Vienna, Austria), Andrea Arrossi (Cleveland Clinic, Cleveland, OH, USA)

Session 5: Multi-system syndromes associated with thymic malignancies (70 min)

1. Multisystem disease features associated with thymic malignancies – setting the clinical scenario and its relevance (10 min)

Maria Isabel Leite (Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford, UK)

2. Heart involvement in thymic malignancies (10 min)

Efstratios Koutroumpakis (The University of Texas MD Anderson Cancer Center, Houston, TX, USA)

3. CNS autoimmunity associated with thymic malignancies – spectrum of clinical and laboratory features and management approach (10 min)

Daniele Velardo (IRCCS Ca’ Granda Foundation, Ospedale Maggiore Policlinico, Milan, Italy)

4. Patients with myasthenia gravis and dilemmas: to use or not neuromuscular blocker; postoperative care for ward or ICU? (10 min)

Zerrin Sungur (Istanbul University Istanbul Faculty of Medicine, Istanbul, Turkey)

Q&A (30 min), moderators: Anna Kostera-Pruszczyk (Medical University of Warsaw, Central University Hospital, Warsaw, Poland), Alexander Marx (Universitätsklinikum Mannheim GmbH, Pathologisches Institut, Mannheim, Germany)

Session 6: GREAT DEBATE: Adjuvant treatment in TETs (70 min)

1. Postoperative radiation therapy (PORT) in TNM stage II and stage III TETs  – YES! (10 min)

Maggie Harris (The Christie, Manchester, UK)

2. Postoperative radiation therapy (PORT) in TNM stage II and stage III TETs  – NO! (10 min)

Mitsugu Omasa (Kobe City Nishi-Kobe Medical Center, Kobe City, Japan)

Q&A (15 min), moderator: Stephen Chun (University of Texas, MD Anderson, Houston, TX, USA)

3. Adjuvant chemotherapy – YES! (10 min)

Julian Molina (Mayo Clinic, Rochester, MN, USA)

4. Adjuvant chemotherapy – NO! (10 min)

Heather Wakelee (Stanford Cancer Center, Stanford Cancer Institute, Stanford, USA)

Q&A (15 min), moderator: Frank Detterbeck (Yale University School of Medicine, New Haven, CT, USA)

Tumor Board (80 min) (Recording available when you purchase access to the entire conference)

Presenter: Andrew Brownlee (Cedars-Sinai Medical Center, Los Angeles, USA)

Expert panel: Andre Moreira (New York University Grossman School of Medicine, New York, NY, USA) – pathologist, Katarzyna Blasinska (Institute of Tuberculosis and Lung Diseases, Warsaw, Poland) – diagnostic radiologist, Giuseppe Cardillo (Azienda Ospedaliera San Camillo Forlanini, Rome, Italy) – surgeon, Ritsuko Komaki (Baylor College of Medicine in Houston TX, USA) – radiation oncologist, Nicolas Girard (Institut Curie, Paris, France) – medical oncologist

Moderator: Alper Toker (West Virginia University Heart and Vascular Institute, Morgantown, WV, USA USA)